Aktuellt
SENASTE
Redeye's initial comment on the Q2 report this morning. We see that Moberg Pharma is progressing as planned. The earlier communicated road map for MOB-15 is unchanged. We do not see any surprises and are encouraged by the confirmation of the progress.
LÄS MER
